> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Agenus Posts Third Straight Operating Profit, $11.4 Million, As Armenia Grants First BOT+BAL Approvals
- URL: https://www.bullished.co/agenus-posts-third-straight-operating-profit-11-4-million-as-armenia-grants-first-bot-bal-d1341d58/
- Published: 2026-11-05T18:51:28.000Z
- Updated: 2026-11-05T18:51:28.000Z
- Description: The biotech's cash rose to $86.9 million after a July placement, with funding through 2031 only if warrants are fully exercised.
- Author: Matteo Parrino
- Tags: SEC Filings, AGEN, Industry: Healthcare

Agenus, a clinical-stage biotech developing cancer immunotherapies, reported [$11.4 million in operating income](https://www.sec.gov/Archives/edgar/data/0001098972/000119312526448637/agen-ex99%5F1.htm?ref=bullished.co) for the third quarter, its third straight positive quarter, and said Armenia granted the first marketing authorizations anywhere for its botensilimab and balstilimab combination. The shares fell 10.62% to $6.23 in Thursday trading, from a prior close of $6.97.

## Profit, but not from cash royalties

Total revenue was $31.5 million, against $30.2 million a year earlier. Of that, $25.5 million was non-cash royalty revenue, tied to royalty interests Agenus previously monetized, which the company says generates no cash. Pre-commercial product revenue from patient access programs was $6.0 million, versus $6.4 million in the second quarter.

The operating result compares with a $4.6 million operating loss in the third quarter of 2025\. Net income was $2.8 million for the quarter and $41.4 million for the first nine months of 2026.

## Cash jumps to $86.9 million

Cash, equivalents and short-term investments stood at $86.9 million on September 30, up from $18.7 million at June 30\. The July private placement supplied about $85 million in upfront gross proceeds.

The company expects that money to cover the Phase 3 ROBBIN trial's start, regulatory work and operations through the third quarter of 2027\. Milestone-aligned warrants could add up to about $255 million if fully exercised, and only on that assumption does the company expect funding to last through year-end 2031.

## Armenia's first approvals

Armenia's Ministry of Health granted authorizations for Botvymo (botensilimab) and Evamplix (balstilimab), used together in adults with previously treated microsatellite-stable metastatic colorectal cancer without active liver metastases. The authorizations are conditional and valid for one year, renewable based on annual clinical updates. Outside Armenia the combination remains investigational and is not FDA-approved.

Agenus, which also owns about 46% of MiNK Therapeutics as of December 31, 2025, is staking its future on the pair. CEO Garo H. Armen said the company has "a clear registrational path and financing aligned with key development milestones anticipated in 2027."

## The Phase 3 bet on colon cancer

ROBBIN is designed with FDA feedback to enroll about 850 patients with high-risk Stage II and III microsatellite-stable colon cancer, given the drugs before surgery. The company says no new curative-intent therapies have been approved for this group in more than two decades, and puts the annual U.S. market above $7 billion.

Two Phase 2 studies, NEST and UNICORN, each reported [pathologic complete responses](https://finance.yahoo.com/healthcare/articles/agenus-announces-nature-medicine-publication-114200083.html?ref=bullished.co) in about 30% of patients, with no recurrences at the cutoffs reported.

Agenus plans to enroll the first ROBBIN patient in the first quarter of 2027, and will present BOT+BAL data at SITC 2026 in November.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — AGENUS INC (AGEN)](https://www.sec.gov/Archives/edgar/data/0001098972/000119312526448637/agen-20261105.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit agen-ex99\_1.htm — AGENUS INC 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001098972/000119312526448637/agen-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=600-202611050730BIZWIRE%5FUSPRX%5F%5F%5F%5F20261105%5FBW453521-1&ref=bullished.co) — Financial Times
- [Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=600-202611021805BIZWIRE%5FUSPRX%5F%5F%5F%5F20261102%5FBW477263-1&ref=bullished.co) — Financial Times
- [Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer](https://finance.yahoo.com/healthcare/articles/agenus-announces-nature-medicine-publication-114200083.html?ref=bullished.co) — Yahoo Finance